SIBO: The Trail of a

Ziad      Fajloun; Ziad      Abi Khattar; Hervé      Kovacic; Christian      Legros; Jean-Marc      Sabatier
[1]
Johnston KL. Small intestinal bacterial overgrowth. Vet Clin North Am Small Anim Pract  1999; 29(2): 523-50.

[2]
Ali A, Mathew R, Jadeja S, Schey R, Masri G. Small intestinal bacterial overgrowth after COVID-19 infection. Am J Gastroenterol  2021; 116: S1243-4.
 [http://dx.doi.org/10.14309/01.ajg.0000785556.20456.40]

[3]
Ahmed J, Padam P, Ruban A. A retrospective analysis of patients on a waiting list for small intestinal bacterial overgrowth (SIBO) breath testing during the COVID-19 pandemic and introduction of a home testing pathway. United European Gastroenterol J  2021; 9 (Suppl. 8): 342.

[4]
Alharbi KS, Singh Y, Hassan Almalki W, et al. Gut microbiota disruption in COVID-19 or post-COVID illness association with severity biomarkers: A possible role of pre/pro-biotics in manipulating microflora. Chem Biol Interact  2022; 358: 109898.
 [http://dx.doi.org/10.1016/j.cbi.2022.109898] [PMID: 35331679]

[5]
Jaworska K, Koper M, Ufnal M. Gut microbiota and renin-angiotensin system: A complex interplay at local and systemic levels. Am J Physiol Gastrointest Liver Physiol  2021; 321(4): G355-66.
 [http://dx.doi.org/10.1152/ajpgi.00099.2021] [PMID: 34405730]

[6]
Fajloun Z, Kovacic H, Annweiler C, Wu Y, Cao Z, Sabatier JM. SARS-CoV-2-induced neurological disorders in symptomatic COVID-19 and long COVID patients: Key role of brain renin-angiotensin system. Infect Disord Drug Targets  2022; 22(5): e060422203203.
 [http://dx.doi.org/10.2174/1871526522666220406124618] [PMID: 35388764]

[7]
El-Arif G, Farhat A, Khazaal S, et al. The renin-angiotensin system: A key role in SARS-CoV-2-induced COVID-19. Molecules  2021; 26(22): 6945.
 [http://dx.doi.org/10.3390/molecules26226945] [PMID: 34834033]

[8]
Khazaal S, Harb J, Rima M, et al. The pathophysiology of long COVID throughout the renin-angiotensin system. Molecules  2022; 27(9): 2903.
 [http://dx.doi.org/10.3390/molecules27092903] [PMID: 35566253]

[9]
Dukowicz AC, Lacy BE, Levine GM. Small intestinal bacterial overgrowth: A comprehensive review. Gastroenterol Hepatol  2007; 3(2): 112-22.
 [PMID: 21960820]

[10]
Buret AG, Motta JP, Allain T, Ferraz J, Wallace JL. Pathobiont release from dysbiotic gut microbiota biofilms in intestinal inflammatory diseases: A role for iron? J Biomed Sci  2019; 26(1): 1.
 [http://dx.doi.org/10.1186/s12929-018-0495-4] [PMID: 30602371]

[11]
Sachdev AH, Pimentel M. Gastrointestinal bacterial overgrowth: Pathogenesis and clinical significance. Ther Adv Chronic Dis  2013; 4(5): 223-31.
 [http://dx.doi.org/10.1177/2040622313496126] [PMID: 23997926]

[12]
El-Arif G, Khazaal S, Farhat A, et al. Angiotensin II Type I receptor (AT1R): The gate towards COVID-19-associated diseases. Molecules  2022; 27(7): 2048.
 [http://dx.doi.org/10.3390/molecules27072048] [PMID: 35408447]

[13]
Annweiler C, Cao Z, Papon N, Kovacic H, Sabatier JM. Counter-regulatory renin-angiotensin system: An important line of research to understand and limit the severity of COVID-19. Infect Disord Drug Targets  2022; 22(2): e100921196331.
 [http://dx.doi.org/10.2174/1871526521666210910063227] [PMID: 34515015]

[14]
Harb J, Debs N, Rima M, et al. SARS-CoV-2, COVID-19, and reproduction: Effects on fertility, pregnancy, and neonatal life. Biomedicines  2022; 10(8): 1775.
 [http://dx.doi.org/10.3390/biomedicines10081775] [PMID: 35892675]

[15]
Sabatier J-M, Fajloun Z, Legros C. COVID-19 and Ehlers-Danlos syndrome: The dangers of the Spike protein of SARS-CoV-2. Infect Disord Drug Targets  2023; 23. Epub ahead of print
 [http://dx.doi.org/10.2174/1871526523666230104145108] [PMID: 36600622]

[16]
Annweiler C, Cao Z, Wu Y, et al. Counter-regulatory ‘Renin-Angiotensin’ system-based candidate drugs to treat COVID-19 diseases in SARS-CoV-2-infected patients. Infect Disord Drug Targets  2020; 20(4): 407-8.
 [http://dx.doi.org/10.2174/22123989MTA2cNzIlw] [PMID: 32418532]
Cite As
Infectious Disorders - Drug Targets

SIBO: The Trail of a "New" Human Pathology Associated with Multiple Severe and Disabling COVID-19 and Long COVID Symptoms or Induced by the Anti-COVID-19 Vaccine
